HLA B57:01 Molecular Detection
Desired Epic Build
* = editable field
Cerner Primary Mnemonic: | HLX HLA Antigen B5701 Case |
PDM | 228468 |
Informatics - Workgroup | Molpath inhouse |
Synonyms * | Abacavir Sensitivity HLAB5701 HLA-B 5701 Genotype HLA Antigen B5701 Abacavir hypersensitivity genotyping |
Display Name * | HLA B57:01 Molecular Detection |
Specimen Sources (combined Order Entry and Specimen Navigator) * | |
Specimen Types (combined Order Entry and Specimen Navigator) * |
Blood
|
Body Fluids (types sent through AOEs) | |
Specimen Navigator Specimen Types | |
Specimen Navigator Specimen Sources | |
Specimen Navigator Short Name | |
Ordering info (EPIC SmartText) | Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-naïve patients. Patients testing positive should not be treated with a regimen containing abacavir. |
IP Orderable (inpatient) | Yes |
OP Orderable (outpatient) | Yes |
AOEs * | |
AP AOEs | |
Special History | No |
Build Comments | |
Filter * | genetics |
Cerner Site Restrict | |
Cerner Results |
Actual Epic Build 3/11/2025
PROCEDURE ID | 115147 | ||||||||||||
PDM | 228468 | ||||||||||||
ORDER DISPLAY NAME | HLA B57:01 Molecular Detection | ||||||||||||
PROCEDURE NAME | HLX HLA B57-1 ANTIGEN CASE | ||||||||||||
PROCEDURE MASTER NUMBER | LAB11403 | ||||||||||||
SHORT PROCEDURE NAME | HLX HLA B57-1 ANTIGEN CASE | ||||||||||||
CATEGORY CODE | 21.0 | ||||||||||||
CATEGORY CODE RECORD NAME | LAB MOLECULAR DIAGNOSTICS ORDERABLES | ||||||||||||
SYNONYMS | ABACAVIR SENSITIVITY HLAB5701 HLA-B 5701 GENOTYPE HLA ANTIGEN B5701 ABACAVIR HYPERSENSITIVITY GENOTYPING |
||||||||||||
CLINICALLY ACTIVE | Yes | ||||||||||||
ORDERABLE | Yes | ||||||||||||
PERFORMABLE | Yes | ||||||||||||
FILTER GENOMICS | Generic Genomics Procedure | ||||||||||||
REFERENCE LINK URL | https://labs.northwell.edu/epic/test/115147 | ||||||||||||
ORDERING INSTRUCTIONS | Hypersensitivity to abacavir has been strongly associated with the HLA-B*57:01 allele. DNA-based testing to assess the presence of HLA-B*57:01 offers higher specificity than serologic testing because monoclonal antibodies may show cross-reactivity with other HLA subtypes. The U.S. Food and Drug Administration (FDA) recommends pre-therapeutic screening for the HLA-B*57:01 allele. Routine screening has been shown to reduce the incidence of ABC HSR from 8% to <0.5% in abacavir-navØve patients. Patients testing positive should not be treated with a regimen containing abacavir. |
||||||||||||
DEFAULT SPECIMEN TYPE | Blood | ||||||||||||
SPECIMEN TYPE PICK LIST | Blood | ||||||||||||
SPECIMEN TYPE LIST | |||||||||||||
OP SPECIMEN TYPE LIST | |||||||||||||
SPECIMEN SOURCE PICK LIST | Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||||||
SPECIMEN SOURCE DEFAULT - MALE | Blood, Venous | ||||||||||||
SPECIMEN SOURCE DEFAULT - FEMALE | Blood, Venous | ||||||||||||
SPECIMEN SOURCE LIST | |||||||||||||
OP SPECIMEN SOURCE LIST | |||||||||||||
IP LAB TEST COMPONENTS FOR REPORT | HLXB57501 | ||||||||||||
OP LAB TEST COMPONENTS FOR REPORT | HLXB57501 | ||||||||||||
ORDER QUESTIONS | ["3048500000"] | ||||||||||||
ORDER QUESTIONS RECORD NAME | |||||||||||||
INPATIENT ORDER QUESTIONS | ["3048500000"] | ||||||||||||
INPATIENT ORDER QUESTIONS RECORD NAME | |||||||||||||
ORDER SPECIFIC QUESTION OVERRIDE | |||||||||||||
INPATIENT QUESTION OVERRIDE | |||||||||||||
LOCATION RESTRICT LIST IP | |||||||||||||
LOCATION RESTRICT LIST IP RECORD NAME | |||||||||||||
LOCATION RESTRICT LIST INCLUDE IP | |||||||||||||
LOCATION RESTRICT LIST OP | |||||||||||||
LOCATION RESTRICT LIST OP RECORD NAME | |||||||||||||
LOCATION RESTRICT LIST INCLUDES OP | |||||||||||||
EDP AMB ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
EDP IP ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
EDP IP SPECIMEN SOURCE | |||||||||||||
EDP OP SPECIMEN SOURCE | |||||||||||||
EDP IP SPECIMEN TYPE | |||||||||||||
EDP OP SPECIMEN TYPE | |||||||||||||
DERIVED EDP IP BUTTONS S | |||||||||||||
DERIVED EDP IP BUTTONS T | |||||||||||||
DERIVED EDP OP BUTTONS S | |||||||||||||
DERIVED EDP OP BUTTONS T | |||||||||||||
IP ORDERABLE | 1 | ||||||||||||
OP ORDERABLE | 1 | ||||||||||||
STANDARD LAB COMPONENTS | |||||||||||||
STANDARD LAB COMPONENTS RECORD NAME | |||||||||||||
COMPONENT DATA REQUIREMENT | |||||||||||||
EPIC OP AOEs
| |||||||||||||
EPIC IP AOEs
| |||||||||||||
EPIC Components (results - crosswalked through Cerner) |